Scientific Advisory

Charles V. Olson, DSc

Director, and Chair of Scientific Advisory Board

Dr. Charles Olson is a biotechnology industry professional with broad scientific and operational experience, and specialization in manufacturing operations and process development of biological products. Dr. Olson currently serves as the Vice President of Biologics for Applied Molecular Transport Inc. His background includes the positions of Chief Technology Officer for Anthera Pharmaceuticals; Vice President of CMC and Technical Operations for NGM Biopharmaceuticals; Senior VP of Product Development and Operations for Nexbio Inc.; VP of Hayward Operations for Cell Genesys; Senior Director of Manufacturing, Facilities and Process Development for Biomarin Pharmaceuticals; Director of Manufacturing Sciences for Onyx Pharmaceuticals; and Staff Scientist and Scientist at Bayer and Genentech, respectively. Dr. Olson received his D.Sc. in Biochemistry from Hawthorne University.

Andrew Saxon, M.D.

Member, Scientific Advisory Board

Dr. Saxon received his medical degree from Harvard Medical School. He is board certified in Internal Medicine, Allergy and Clinical Immunology and Diagnostic/Laboratory Immunology and a Professor of Medicine at UCLA. He has published over 180 peer reviewed research publications primarily dealing the control and assessment of the human immune response. Dr. Saxon and colleagues at UCLA were the first to recognize AIDS in 1980, brought this new disease to the attention of the CDC in 1981, and published the first research publication describing this disease in the New England Journal of Medicine that same year. Dr. Saxon and his collaborators have made seminal discoveries on the mechanisms that control human antibody responses and particularly allergic antibodies (IgE) as well as pioneered research into the role of environmental factors in the modulation of the human immune response. As part of his work, Dr. Saxon has had extensive experience with the KLH in its various molecular forms. Dr. Saxon served for a decade as the Editor-in-Chief of Clinical Immunology, the official journal of the Clinical Immunology Society. He has founded two biotech companies focused on the prevention of allergic reactions in humans.

Connect with Us